CEO Su-Leng Tan Lee Receives 338,709 Fully Vested Shares, Boosting Stake to 11.5%
BGLC sits 47% above its 52-week low of $1.07.
Summary
BioNexus Gene Lab Corp granted CEO Su-Leng Tan Lee 338,709 fully vested shares, increasing her beneficial ownership to 11.5% of the company.
Key Events · Ownership and Investor Activity · BGLC
-
CEO Receives 338,709 Shares
Su-Leng Tan Lee, CEO and President, was granted 338,709 fully vested shares on August 13, 2026, for completed services and no cash consideration.
-
Stake Rises to 11.5%
The award increases her beneficial ownership to 338,709 shares, representing approximately 11.5% of outstanding common stock.
-
Award Valued at $524,999
The shares were valued at $1.55 each, the Nasdaq closing price on August 12, 2026, for an aggregate Plan value of $524,998.95.
-
Regulation S Offshore Issuance
The shares were issued outside the U.S. under Regulation S, subject to a six-month distribution compliance period and transfer restrictions.
Analysis · BGLC · Industrial Applications And Services
A fully vested stock award of 338,709 shares, representing 11.5% of the company, was granted to the CEO and President for no cash consideration. This significant equity grant aligns management with shareholders but also dilutes existing holders. The award was issued under Regulation S, restricting resale for six months. Given the company's recent revenue collapse and going concern doubts, this grant may be seen as a retention tool or a signal of confidence, but it also raises questions about compensation practices during financial distress.
At the time of this filing, BGLC was trading at $1.57 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $3.8M. The 52-week trading range was $1.07 to $6.10. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.